Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky sells 3,000 shares for $75,000
Reuters2026/08/12 23:34- Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky sold 3,000 common shares on Aug. 10, 2026 at USD 25.
- Post-transaction holdings totaled 396,989 shares.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas
A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

Franco-Nevada buys A$170 million Bullabulling gold project royalty from Minerals 260

10-Yr Benchmark Govt Yields - Germany vs Other Nations